Go to the list of all blogs
Bort Wilson's Avatar
published in Blogs
Sep 23, 2026
TickeronGET DAILY SIGNALS
Why Is Astrana Health (ASTH) Stock Down -5.53% Today?

Why Is Astrana Health (ASTH) Stock Down -5.53% Today?

Key Takeaways

  • Shares of ASTH fell 5.53% to $33.17, a decline of $1.94 from the prior session's close of $35.11.
  • The primary catalyst was a regulatory filing disclosing a "material" cybersecurity incident at its Astrana Health Management subsidiary.
  • The incident involved social engineering, with threat actors impersonating employees and spoofing the company's corporate phone number.
  • The drop compounds pressure from a recent GlassHouse Research short-seller report questioning the company's acquisition-driven growth.
  • The move was largely company-specific, as the broader healthcare sector traded near flat.
  • Traders are now watching for further detail on the breach's scope and any operational or client impact.

Opening Summary

Astrana Health, Inc. (ASTH), a physician-centric, technology-enabled healthcare company that provides care coordination and value-based care enablement across the United States, saw its stock fall sharply on Wednesday. Shares closed the prior session at $35.11 and traded down to $33.17 during the session, a decline of 5.53%. The selling was triggered by a cybersecurity disclosure filed with regulators, which markets interpreted as a meaningful new risk for the company.

Catalyst Breakdown: Cybersecurity Incident Disclosure

The sharpest driver of the decline was Astrana Health's announcement, via a regulatory filing, that its Astrana Health Management subsidiary had detected unusual activity in its systems. The company determined that the incident is "material" because of the potential confidential and sensitive nature of the data involved. According to the filing, the intrusion involved social-engineering attempts in which threat actors impersonating Astrana employees and spoofing the company's corporate telephone number contacted staff to gain access to its systems.

Astrana Health said its cybersecurity team responded to the unauthorized activity, launched an investigation, engaged a third-party digital forensics firm, and notified law enforcement and regulators. The market reaction reflects investor concern that a data breach involving protected health information could carry remediation costs, regulatory scrutiny, and reputational risk—particularly for a business built on managing sensitive patient and payer data across provider networks.

Secondary Pressure: Short-Seller Report and Valuation Concerns

The cybersecurity news landed on top of already-heightened scrutiny of the stock. Earlier in the week, GlassHouse Research published a short-seller report arguing that Astrana Health's reported growth depends on a "continuous, debt-funded" acquisition pipeline and that its growth narrative "nearly disappears" without acquisitions. That report triggered a notable decline in the shares. The combination of the short thesis and the new cyber disclosure left investors with two overlapping sources of uncertainty, amplifying the selling pressure.

The stock had also rallied strongly earlier in the year, leaving it trading at a valuation premium relative to the broader healthcare sector. When company-specific risk events emerge on an elevated multiple, profit-taking and de-risking can be more pronounced, which likely contributed to the magnitude of the move.

Market Context and Trading Activity

The decline in ASTH was driven primarily by company-specific news rather than broad sector weakness, with healthcare indices trading relatively stable during the session. The stock has been volatile in recent sessions, moving from above $38 earlier in the month to a recent intraday low near $32.22 before a rebound into the low-to-mid $30s. Wednesday's slide pushed the shares back toward the lower end of that recent range, suggesting that investors are testing support levels established during the prior week's selloff.

The move also followed a period of insider selling disclosed in recent regulatory filings, which some market participants read as an incremental signal of caution even though such transactions are routine and often pre-scheduled. Taken together, the technical backdrop and news flow reinforced a defensive posture among holders.

What Comes Next for ASTH

Investors will now focus on the outcome of the company's forensic investigation, including the specific scope of data potentially accessed and whether the incident affects operations, clients, or payer relationships. Any regulatory follow-up or litigation risk stemming from the breach will also be closely monitored.

Beyond the immediate cybersecurity issue, the market will weigh the company's third-quarter results, which are expected to reflect continued integration of recent acquisitions and progress in its value-based care arrangements. Analyst sentiment heading into the event remained broadly constructive, but the short-seller report and breach disclosure have introduced new variables. Risks include further adverse findings from the investigation, potential financial or operational disruption, and renewed pressure on the company's valuation if growth expectations are reassessed.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots page to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ASTH

Contributor

Bort Wilson's AvatarBort Wilson|Beginner

With a background in economics and swing trading, I write about market trends, technical setups, momentum, and opportunities that develop over several days or weeks. I combine economic perspective with practical trading experience to explain why stocks move, what trends may be developing, and which market signals are worth watching.


ASTH in -10.35% downward trend, declining for three consecutive days on November 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ASTH declined for three days, in 232 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASTH as a result. In 62 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for ASTH turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 29 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

ASTH moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ASTH crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 57%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASTH advanced for three days, in 240 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

ASTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 136 of 195 cases where ASTH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ASTH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.099) is normal, around the industry mean (204.532). P/E Ratio (42.878) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (0.485) is also within normal values, averaging (2.688).

The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 0%. CHE experienced the highest price growth at 0%, while NIVF experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 49
Price Growth Rating: 59
SMR Rating: 66
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry HospitalNursingManagement

Industry
N/A
Address
1668 South Garfield Avenue
Phone
+1 626 282-0288
Employees
3000
Web
https://www.astranahealth.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.